Arvinas, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ARVN Nasdaq 2830 www.arvinas.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arvinas, Inc.

Rigel Pharmaceuticals Inc (RIGL) (Q3 2026) Earnings Call Highlights: Record Product Sales of ... - Nov 6th, 2026 12:14 pm
Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting - Nov 4th, 2026 2:01 pm
What Arvinas Bears Saw Before The Fall - Nov 4th, 2026 1:11 am
Arvinas, Inc. Q3 2026 Earnings Call Summary - Nov 3rd, 2026 7:41 pm
Arvinas Inc (ARVN) (Q3 2026) Earnings Call Highlights: Cost Cuts, $558. ... - Nov 3rd, 2026 6:04 pm
Arvinas (ARVN) Q3 2026 Earnings Call Transcript - Nov 3rd, 2026 2:43 pm
What Arvinas (ARVN) Said on Its Q3 Earnings Call - Nov 3rd, 2026 8:14 am
Arvinas, Inc. (ARVN) Reports Q3 Loss, Misses Revenue Estimates - Nov 3rd, 2026 5:40 am
Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update - Nov 3rd, 2026 5:00 am
Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation - Oct 27th, 2026 2:01 pm
Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026 - Oct 27th, 2026 5:00 am
Could You Have Seen The Run In Kymera Stock Coming? - Oct 26th, 2026 3:34 pm
Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth? - Oct 19th, 2026 7:08 am
Roche Gets FDA Approval for Enspryng in Thyroid Eye Disease - Oct 16th, 2026 8:21 am
KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome - Oct 16th, 2026 8:19 am
Reasons Why Investors Should Consider Betting on Arvinas Stock - Oct 13th, 2026 8:27 am
TGTX Stock Rises 60% in 6 Months: Here's What You Should Know - Oct 13th, 2026 7:47 am
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases - Oct 13th, 2026 7:41 am
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease - Oct 7th, 2026 5:00 am